All Metrics
EW Valuation Metrics
EW Stock Price Metrics
EW Dividend Metrics
EW Growth Rate Metrics
EW Discounted Cash Flow Metrics
| Fair Value Price | $64.15 |
| Margin of Safety | (29.34%) |
EW Revenue Metrics
EW PE Ratio Metrics
| PE Ratio | 48.29 |
| PE Ratio Avg TTM | 30.01 |
| PE Ratio Avg 3Y | 27.55 |
| Current VS TTM Avg | +60.93% |
| Current VS 3Y Avg | +75.25% |
| Current VS 5Y Avg | +46.69% |
EW PS Ratio Metrics
| PS Ratio | 8.36 |
| PS Ratio Avg TTM | 8.09 |
| PS Ratio Avg 3Y | 8.05 |
| Current VS TTM Avg | +3.29% |
| Current VS 3Y Avg | +3.84% |
| Current VS 5Y Avg | -11.44% |
EW PB Ratio Metrics
| PB Ratio | 5.10 |
| PB Ratio Avg TTM | 4.62 |
| PB Ratio Avg 3Y | 5.68 |
| Current VS TTM Avg | +10.48% |
| Current VS 3Y Avg | -10.22% |
| Current VS 5Y Avg | -34.34% |
EW Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 48.39 |
| PFCF Ratio Avg TTM | 58.49 |
| PFCF Ratio Avg 3Y | 66.72 |
| Current VS TTM Avg | -17.26% |
| Current VS 3Y Avg | -27.47% |
| Current VS 5Y Avg | -20.71% |
EW Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.07 |
| Debt/Equity Ratio Avg TTM | 0.07 |
| Debt/Equity Ratio Avg 3Y | 0.09 |
| Current VS TTM Avg | -0.09% |
| Current VS 3Y Avg | -19.95% |
| Current VS 5Y Avg | -31.62% |
EW PEG Ratio Metrics
| PEG Ratio | 7.03 |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 5.11 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | +37.66% |
| Current VS 5Y Avg | +72.30% |
EW FCF Yield
| FCF Yield | 2.07% |
| FCF Yield Avg TTM | 1.84% |
| FCF Yield Avg 3Y | 1.46% |
| Current VS TTM Avg | +12.25% |
| Current VS 3Y Avg | +41.67% |
| Current VS 5Y Avg | +24.76% |
EW Earnings Yield
| Earnings Yield | 2.07% |
| Earnings Yield Avg TTM | 4.84% |
| Earnings Yield Avg 3Y | 5.01% |
| Current VS TTM Avg | -57.26% |
| Current VS 3Y Avg | -58.67% |
| Current VS 5Y Avg | -21.86% |
EW EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 29.28 |
| Ev/Ebit Ratio Avg TTM | 29.08 |
| Ev/Ebit Ratio Avg 3Y | 28.80 |
| Current VS TTM Avg | +0.68% |
| Current VS 3Y Avg | +1.67% |
| Current VS 5Y Avg | -10.72% |
EW EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 26.80 |
| Ev/Ebitda Ratio Avg TTM | 26.44 |
| Ev/Ebitda Ratio Avg 3Y | 26.10 |
| Current VS TTM Avg | +1.35% |
| Current VS 3Y Avg | +2.70% |
| Current VS 5Y Avg | -9.96% |
EW EV/Assets Ratio Metrics
| Ev/Assets Ratio | 3.83 |
| Ev/Assets Ratio Avg TTM | 3.40 |
| Ev/Assets Ratio Avg 3Y | 4.06 |
| Current VS TTM Avg | +12.78% |
| Current VS 3Y Avg | -5.72% |
| Current VS 5Y Avg | -29.25% |
EW EV/Sales Ratio Metrics
| Ev/Sales Ratio | 8.09 |
| Ev/Sales Ratio Avg TTM | 7.72 |
| Ev/Sales Ratio Avg 3Y | 7.75 |
| Current VS TTM Avg | +4.82% |
| Current VS 3Y Avg | +4.43% |
| Current VS 5Y Avg | -14.43% |
EW Current Ratio Metrics
| Current Ratio | 4.42 |
| Current Ratio Avg TTM | 4.26 |
| Current Ratio Avg 3Y | 3.78 |
| Current VS TTM Avg | +3.88% |
| Current VS 3Y Avg | +16.81% |
| Current VS 5Y Avg | +22.01% |
EW Quick Ratio Metrics
| Quick Ratio | 3.63 |
| Quick Ratio Avg TTM | 3.51 |
| Quick Ratio Avg 3Y | 3.00 |
| Current VS TTM Avg | +3.42% |
| Current VS 3Y Avg | +21.02% |
| Current VS 5Y Avg | +28.30% |
EW ROIC Metrics
| ROIC | 11.40% |
| ROIC Avg 3Y | 14.43% |
| ROIC Avg 5Y | 15.83% |
| Current VS 3Y Avg | -21.00% |
| Current VS 5Y Avg | -27.97% |
| Current VS 10Y Avg | -29.42% |
EW Return on Assets Metrics
| ROA | 7.84% |
| ROA Avg TTM | 19.91% |
| ROA Avg 3Y | 18.29% |
| Current VS TTM Avg | -60.62% |
| Current VS 3Y Avg | -57.13% |
| Current VS 5Y Avg | -53.98% |
EW Return on Equity Metrics
| ROE | 10.38% |
| ROE Avg TTM | 26.07% |
| ROE Avg 3Y | 24.86% |
| Current VS TTM Avg | -60.18% |
| Current VS 3Y Avg | -58.24% |
| Current VS 5Y Avg | -56.51% |
EW Net Profit Margin Metrics
| Net Profit Margin | 23.09% |
| Net Profit Margin Avg TTM | 18.90% |
| Net Profit Margin Avg 3Y | 25.13% |
| Current VS TTM Avg | +22.17% |
| Current VS 3Y Avg | -8.11% |
| Current VS 5Y Avg | -12.95% |
Last Updated: Sunday, June 28, 2026
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian